|
Patent landscape, scope, and claims summary: |
US Patent 10,179,228 Claim Scope and U.S. Patent Landscape Analysis
Executive summary: U.S. Patent 10,179,228 claims an ingestible, swallowable capsule delivering a solid protein/polypeptide in a tissue-penetrating member inserted into the small-intestinal wall, using a release element responsive to a condition in the small intestine to enable local delivery while inhibiting chemical degradation of the protein/polypeptide in the intestinal lumen. Dependent claims broaden coverage across biodegradable penetration materials, pH-triggered degradation, actuated insertion mechanisms (including expandable gas-forming systems), and a wide therapeutic set (notably diabetes agents including insulin and GLP-1 / incretin / exenatide with metformin, plus growth hormone, parathyroid hormone, antibiotics, antivirals, and gamma globulins/antibodies). The patent’s breadth creates a large intersection with existing oral protein delivery and intestinal wall-localization concepts, but the claim’s strongest enforceability anchors are the specific delivery architecture: solid protein in capsule, tissue-penetrating member, release to insert into small-intestinal wall, and degradation inhibition in the lumen triggered/controlled by a release element.
What patents protect ingestible capsules that deliver proteins into the small-intestinal wall without degrading in the lumen?
What claim 1 requires (core independent claim):
Claim 1 is the primary enforceable backbone. It requires, in combination:
- Ingestible device sized for swallowing and passage through GI tract (capsule format).
- Preparation inside capsule containing a solid therapeutic agent comprising a protein or polypeptide.
- The preparation is shaped as a tissue penetrating member configured to be inserted into the wall of a small intestine.
- The preparation includes at least one protein/polypeptide that chemically degrades if released within the lumen.
- A release element coupled to the therapeutic agent preparation.
- The release element releases the solid therapeutic agent from the capsule into the wall of the small intestine responsive to a condition in the small intestine.
- When released into the wall, chemical degradation in the lumen is inhibited.
Critical scope points that drive infringement and validity risk:
- The patent is not a general “oral protein delivery” claim. It is tied to lumen-to-wall delivery with a release responsive to an intestinal condition, and a functional degradation-inhibition outcome.
- “Solid therapeutic agent” and “tissue penetrating member configured to be inserted into the wall” narrow the architecture versus passive diffusion or surface coating alone.
- “Chemically degrade if released within the lumen” ties the invention to lumen exposure problems (proteolysis, pH denaturation, enzymatic degradation) and can be used to argue non-obviousness over purely encapsulated/protected oral delivery where the lumen exposure is mitigated by polymer shielding rather than wall insertion.
- “Release element responsive to a condition” is broad enough to cover multiple triggers (pH, enzymes, osmolality, fluid contact), but dependent claims stress pH > 7.4 degradation-trigger materials and actuator-activation by release element behavior.
How do dependent claims expand claim 1 protection?
Claim 2 (biodegradable tissue penetrating member):
- Adds that the penetrating member comprises a biodegradable material configured to biodegrade in tissue, releasing the therapeutic agent into the small-intestinal wall.
Claim 3 (biodegradable material examples):
- Narrows/anchors biodegradable composition to sugar, a biodegradable polymer, or PGLA (poly(glycolide-co-lactide)).
Claim 4-5 (pH-triggered release element degradation):
- Release element includes a material configured to degrade on exposure to a selected pH.
- Selected pH is greater than about 7.4. This is a critical numeric anchor that can both support validity arguments over prior pH ranges and create design-around opportunities if an implementer uses a different pH window or non-degrading triggers.
Claim 6-8 (actuated wall insertion):
- Adds an actuator coupled to the release element that advances the penetrating member into the wall.
- Actuator can be an expandable member (claim 7) or a piston/plunger (claim 8). This creates multiple mechanical infringement paths.
Claim 7 (expandable gas-forming system):
- Expandable member within capsule; two compartments separated by a releasable valve.
- Valve releases upon exposure to intestinal fluid.
- Reactants mix to produce gas expanding expandable member.
- A delivery member coupled to expandable member and penetrating member advances the tissue penetrating member.
Claim 9 (release element comprises the releasable valve):
- Release element can be the valve that triggers both compartment opening and subsequent actuation.
Claims 10-17 (therapeutic payload coverage for diabetes/glucose regulation):
- Claim 10 makes the general payload a therapeutically effective dose of a therapeutic agent.
- Claim 11 covers insulin.
- Claim 12 covers incretins and diabetes/glucose regulation.
- Claim 13 enumerates incretins/analogues: GLP-1, GLP-1 analogues, exenatide, liraglutide, albiglutide, taspoglutide, GIP.
- Claim 14 covers combinations.
- Claim 15 covers incretin + biguanide combinations.
- Claim 16 specifies exenatide + metformin.
- Claim 17 adds matching dose ratios for improved blood glucose control over an extended period. This becomes a dependent claim that may require proof of dose-matching strategy in any accused product.
Claims 18-24 (other therapeutic classes and biologics):
- Claim 18: growth hormone.
- Claim 19: parathyroid hormone for osteoporosis or thyroid disorder.
- Claim 20: antibiotic.
- Claim 21: antiviral; claim 22 specifies protease inhibitor.
- Claim 23: gamma globulin.
- Claim 24: gamma globulin as an antibody with delivery into wall of small intestine with minimal or no loss in binding affinity/specificity.
What is the patent’s claim strength: architecture vs therapeutic breadth?
- Architecture-focused elements (capsule, solid protein, tissue penetrating member, release responsive to intestinal condition, local insertion into small-intestinal wall, inhibited degradation) are the most likely to be sustained in enforceability and are the main sources of novelty over prior “protect-and-release” oral strategies.
- Therapeutic payload breadth is large and can be challenged if prior art already disclosed oral delivery of many of these proteins using similar insertion/trigger concepts. Still, the specific combination of insertion + lumen-protection-by-localization can support non-obviousness even with common payloads.
When does US Patent 10,179,228 expire and what exclusivity risks exist for oral protein delivery?
Sole basis available: The prompt provides only the claim text, not:
- filing date, priority date, or patent issue date details for 10,179,228, or
- family member filing/priority structure,
- maintenance status or terminal disclaimer structure.
Without those, an exclusivity timeline and expiration computation cannot be produced accurately.
What does the claim coverage imply for Paragraph IV generic or biosimilar entry risk?
Critical point: This is a patent on an ingestible device/delivery system, not a standalone method-of-treatment claim only. That changes the risk profile:
- Generic/biosimilar product-identity arguments are less direct if a generic/biosimilar would still use a different delivery system.
- Potential infringement likely turns on whether an accused oral capsule uses the same device architecture: capsule + solid protein in tissue-penetrating member + insertion into small-intestinal wall + condition-responsive release element inhibiting lumen degradation.
Biosimilar angle: If the payload is insulin, GLP-1 analogues, or antibodies, biosimilars could still be viable if they can avoid the delivery-system claim by using alternative oral protection routes (enteric coatings, enzymatic inhibitors, non-penetrating absorption enhancers, intraluminal release to systemic absorption).
What formulations are protected by US Patent 10,179,228?
Protected formulation concept (not chemical formula):
- A solid therapeutic agent comprising protein/polypeptide is disposed in a capsule.
- The agent is shaped as a tissue penetrating member for insertion into the small intestine wall.
- The release element releases the solid therapeutic agent into the wall responsive to a condition (pH-based degradation is explicitly claimed).
Material and trigger formats explicitly claimed:
- Biodegradable penetration material including PGLA and sugar.
- Release element that degrades at pH > 7.4.
- Actuation by expandable gas-forming system using two-compartment reactants separated by a valve actuated by intestinal fluid exposure.
Design-around levers suggested by the claim language (scope boundaries):
- Use a non-degrading release mechanism rather than “material configured to degrade upon exposure to pH > 7.4.”
- Use different insertion mechanics than actuator coupled to expandable member/piston/plunger pathways, or avoid local insertion as claimed.
- Avoid “solid therapeutic agent” shaped as the penetrating member; use liquid/gels that do not form a tissue penetrating member.
What patent litigation affects US Patent 10,179,228?
No litigation dockets, parties, or asserted-claim history are provided in the prompt. Without case identifiers and public records, a definitive litigation-impact analysis cannot be created.
Which companies are likely to face infringement exposure under these claims?
No assignee information, listed inventors, or “who commercializes oral wall-penetrating protein capsules” for this specific patent is provided. Without those, naming specific companies would be speculative.
How does US Patent 10,179,228 compare with other oral peptide and protein delivery patent estates?
A complete comparison needs:
- the independent technical prior art set (oral protein capsules, mucoadhesive patches, enteric release systems, intestinal wall-penetrating devices, pH-triggered triggers, expandable actuation capsules), and
- citation mapping from the patent (prior-art references listed in the patent document),
- plus competitor patent families and grant status in the U.S.
The prompt provides only claim text. A patent-family-level comparison cannot be completed without the underlying references and prosecution history.
Key Takeaways
- US 10,179,228 claim 1 is centered on a capsule-delivered, solid protein/polypeptide, tissue-penetrating member inserted into the small-intestinal wall, with a condition-responsive release element that inhibits protein chemical degradation in the lumen.
- Dependent claims materially broaden or narrow scope via:
- biodegradable penetrating member materials (including PGLA),
- pH-triggered degradation of release element (pH > 7.4),
- actuated insertion using expandable gas-forming systems (valve + two reactants) or piston/plunger.
- Therapeutic coverage is broad across insulin, incretins (GLP-1 family including exenatide; GIP), metformin combinations, growth hormone, parathyroid hormone, antibiotics, protease-inhibitor antivirals, gamma globulins, and antibodies with preserved binding.
- The strongest enforceability anchor is the device architecture (wall insertion + lumen degradation inhibition) rather than payload identity alone.
- A complete, critical landscape analysis (expiration timeline, Orange Book status, litigation, competitor families, and claim chart mapping) cannot be produced from claim text alone.
FAQs
- Does US 10,179,228 cover oral delivery that absorbs proteins across intestinal mucosa without penetrating the wall?
- Can a system using an enteric coating instead of a pH>7.4 degradable release element avoid claim 4-5?
- Would an accused product still infringe if it delivers GLP-1 analogues but uses a non-gas actuator mechanism?
- Are antibody delivery embodiments limited by the “minimal or no loss in binding affinity” functional requirement in claim 24?
- How much of the risk is driven by claim 1 architecture versus dependent claims specifying PGLA, pH thresholds, or expandable valve actuation?
References (APA)
- No citable sources were provided in the prompt.
More… ↓
⤷ Start Trial
|
